<p>This study used molecular beacon-modified fluorescent probes (Cy-MB-BHQ) to monitor cannabinoid receptor 1 (CB1R) changes in the cerebrospinal fluid (CSF) of middle cerebral artery occlusion (MCAO) mice and to examine the regulatory roles of CB1R and DEPDC5 in cerebral ischemia-induced epilepsy. A DEPDC5 knockout (KO) mouse model, single-cell omics analysis, an in vitro excitatory-neuron model, CB1R inhibitor intervention, and molecular probe tracking were integrated to evaluate the DEPDC5/mechanistic target of rapamycin (mTOR) signaling axis. DEPDC5 KO aggravated post-ischemic epileptic seizures and was accompanied by enhanced mTOR pathway activation. JD-5037 treatment upregulated DEPDC5 and inhibited mTOR signaling in wild-type (WT)+MCAO mice, whereas this protective effect was weakened in the DEPDC5 KO background. Cy-MB-BHQ application further showed dynamic CB1R changes during ischemia-induced epilepsy, which may be functionally associated with abnormal regulation of the DEPDC5/mTOR signaling axis. These findings support the involvement of the CB1R/DEPDC5/mTOR axis in post-ischemic epileptogenesis and demonstrate the feasibility of molecular beacon probes for monitoring CB1R-associated signals in CSF.</p> Graphical abstract <p></p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Molecular beacon probes uncover CB1R dynamics in cerebrospinal fluid during ischemia-induced epilepsy

  • Lixin Li,
  • Sai Zhang,
  • Qian Wang,
  • Zuying Kuang,
  • Mingzhu Feng,
  • Yucao Sun,
  • Fen Xie,
  • Wenhui Huang,
  • Heng Meng,
  • Zhaofei Dong,
  • Tao Zeng

摘要

This study used molecular beacon-modified fluorescent probes (Cy-MB-BHQ) to monitor cannabinoid receptor 1 (CB1R) changes in the cerebrospinal fluid (CSF) of middle cerebral artery occlusion (MCAO) mice and to examine the regulatory roles of CB1R and DEPDC5 in cerebral ischemia-induced epilepsy. A DEPDC5 knockout (KO) mouse model, single-cell omics analysis, an in vitro excitatory-neuron model, CB1R inhibitor intervention, and molecular probe tracking were integrated to evaluate the DEPDC5/mechanistic target of rapamycin (mTOR) signaling axis. DEPDC5 KO aggravated post-ischemic epileptic seizures and was accompanied by enhanced mTOR pathway activation. JD-5037 treatment upregulated DEPDC5 and inhibited mTOR signaling in wild-type (WT)+MCAO mice, whereas this protective effect was weakened in the DEPDC5 KO background. Cy-MB-BHQ application further showed dynamic CB1R changes during ischemia-induced epilepsy, which may be functionally associated with abnormal regulation of the DEPDC5/mTOR signaling axis. These findings support the involvement of the CB1R/DEPDC5/mTOR axis in post-ischemic epileptogenesis and demonstrate the feasibility of molecular beacon probes for monitoring CB1R-associated signals in CSF.

Graphical abstract